Ilan Shapira is an Oncology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 31 publications with 249 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 Union Sq E
Suite 4c
New York, NY 100033314
Telephone
212-844-8948Registry record last updated 13 Oct 2015.
Clinical trials
- Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma
Sponsor: Beth Israel Medical Center
- Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
- Janssen Biotech, Inc.Program year20254 payments
- Celgene CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49%Kinase inhibitor20.4%Imatinib Mesylate35%Imbruvica32%Bosulif10%Brukinsa10%Jakafi8%Calquence7%Part D<11 patientsThalidomide Analog16.3%Revlimid59%Lenalidomide35%Pomalyst6%Part D<11 patients+ 3 more classes in this area
Blood & clotting
18.1%Factor Xa inhibitor9%Xarelto57%Eliquis43%Part D<11 patientsErythropoiesis-stimulating Agent6.3%Procrit55%Retacrit46%Part D<11 patients+ 1 more class in this area
Anti-infectives
12.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor9.5%Valacyclovir100%Part D≥29 patientsNucleoside and nucleotide reverse transcriptase inhibitors2.2%Tenofovir Disoproxil Fumarate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Danazol and cost-savings in immune thrombocytopenia and in immune thrombotic thrombocytopenic purpura
Blood Coagulation & Fibrinolysis
2025 - Folate deficiency anemia in patients on PARP inhibition: Insights from a large single-center study.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”